Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
BRIEF-Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln June 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
AND SK BIOPHARMACEUTICALS ENTER AI-POWERED RD COLLABORATION WORTH UP TO $2.5 BILLION
TO RECEIVE UP TO $18 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
TOTAL POTENTIAL DEAL VALUE EXCEEDS $2.5 BILLION INCLUDING MILESTONES AND ROYALTIES
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7